← All trials
NCT04418141
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Apr 30, 2022
- First posted
- Jun 5, 2020
- Last posted
- Jun 5, 2020
- Enrollment
- 22
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Curon Biopharmaceutical (Australia) Co Pty LtdLead sponsor
- NovotechCollaborator
- Cabrini Hospital (Melbourne)Overall official - principal investigator
- Icon Cancer Centre (Brisbane)Overall official - principal investigator
- Illawarra Cancer Care Centre (Wollongong)Overall official - principal investigator
- Macquarie University HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.